肿瘤患者肾功能评估:对抗癌药物选择与剂量的影响
本文综述了肿瘤患者肾功能评估的常用方法及其临床影响。Cockcroft-Gault公式仍是肿瘤患者中最广泛使用的估算方法,尽管其准确性不及CKD-EPI方程;而许多现行肾功能切点值是在CKD-EPI方程和肌酐检测标准化之前基于Cockcroft-Gault估算确定的。作者以卡铂和顺铂为例,讨论了不同估算方法对药物剂量、药物选择及临床试验入组资格的影响,并呼吁开展更多研究验证现行估算方法及传统剂量与入组指南对更精确估算方法的适用性。
要点
- Cockcroft-Gault公式仍是肿瘤患者最广泛使用的肾功能估算方法。
- 高估肾功能可致过量用药或选药不当及相关毒性,低估可致剂量不足或错误排除。
- 现行肾功能切点多基于Cockcroft-Gault,需研究其对新估算方法的适用性。
核心结论
- 肿瘤患者肾功能估算方法直接影响药物剂量、药物选择及临床试验入组资格。
- Cockcroft-Gault公式仍最广泛使用,但准确性不及CKD-EPI方程。
- 需更多研究验证现行肾功能估算及传统剂量与入组指南对更精确方法的适用性。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 高估肾功能可能导致过量用药或选药不当及相应毒性。
- 低估肾功能可能导致剂量不足或错误排除及治疗失败。
- 许多现行肾功能切点值在CKD-EPI方程及肌酐检测标准化之前基于Cockcroft-Gault确定。
- 以卡铂和顺铂为案例讨论了不同估算方法对剂量、选药和入组的影响。
临床怎么用
- 临床决策中应认识所用肾功能估算方法对肿瘤药物剂量与选择的影响。
- 使用现行切点值时需注意其多基于Cockcroft-Gault而非CKD-EPI。
- 卡铂和顺铂的剂量与选药可参考本综述讨论的估算方法影响。
局限性
- 为综述,未报告系统检索范围。
- 摘要未报告具体研究数据或验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Estimation of kidney function in patients with cancer directly affects drug dosing, agent selection, and eligibility for clinical trials of novel agents. Overestimation of kidney function may lead to overdosing or inappropriate agent selection and corresponding toxicity. Conversely, underestimation of kidney function may lead to underdosing or inappropriate agent exclusion and subsequent therapeutic failure. It would seem obvious that the most accurate estimates of kidney function should be used to reduce variability in decision making and ultimately, the therapeutic outcomes of toxicity and clinical benefit. However, clinical decision making is often more complex. The Cockcroft-Gault formula remains the most universally implemented estimator of kidney function in patients with cancer, despite its relative inaccuracy compared with the Chronic Kidney Disease Epidemiology Collaboration equation. The Chronic Kidney Disease Epidemiology Collaboration equation is a more precise estimator of kidney function; however, many currently used kidney function cutoff values were determined before the development of the Chronic Kidney Disease Epidemiology Collaboration equation and creatinine assay standardization using Cockcroft-Gault estimates. There is a need for additional studies investigating the validity of currently used estimates of kidney function in patients with cancer and the applicability of traditional anticancer dosing and eligibility guidelines to modern and more accurate estimates of kidney function. In this review, we consider contemporary calculation methods used to estimate kidney function in patients with cancer. We discuss the clinical implications of using these various methods, including the potential influence on drug dosing, drug selection, and clinical trial eligibility, using carboplatin and cisplatin as case studies.
引用
- Casal MA, Nolin TD, Beumer JH, et al. Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing. Clin J Am Soc Nephrol. 2019. PMID: 30890575. doi:10.2215/CJN.11721018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。